Undisclosed pan-KRAS degrader / Arvinas - LARVOL DELTA

Presented preclinical data at the AACR Special Conference in Cancer Research: RAS Oncogenesis and Therapeutics. (The Manila Times) - "Robust efficacy observed in CDX models of pancreatic, colorectal, and lung cancer; Greater tumor growth inhibition than a pan-RAS (ON) inhibitor demonstrated in a KRAS G13D model; Enhanced combination efficacy with immune checkpoint blockade compared with a pan-RAS (ON) inhibitor observed in a KRAS G12D syngeneic model."

Preclinical • Colorectal Cancer • Lung Cancer • Pancreatic Cancer

Anticipated Upcoming Milestones and Expectations (GlobeNewswire) - "ARV-6723: Oral PROTAC HPK1 degrader: Initiate Phase 1 clinical trial in patients with advanced solid tumors (mid-2026, pending regulatory feedback). ARV-6723 is Arvinas’ first immuno-oncology clinical candidate; Present preclinical data evaluating antitumor and unique immunomodulatory activity of ARV-6723 in IO-resistant models compared to standard of care checkpoint inhibition. (1H 2026)....Present preclinical data evaluating the activity and selectivity of novel pan-KRAS degrader in multiple KRAS mutants and differentiation over RAS (ON) or pan-KRAS inhibitors (AACR-RAS, March 2026); Present preclinical data evaluating the efficacy of a novel pan-KRAS degrader in a KRAS syngeneic model, as well as associated immune microenvironment changes (1H 2026)."

New P1 trial • Preclinical • Solid Tumor